Genscript Biotech Corporation (HKG:1548)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 75.32B +99.5% |
| Revenue (ttm) | 6.63B +2.0% |
| Net Income | -4.99B |
| EPS | -2.29 |
| Shares Out | 2.19B |
| PE Ratio | n/a |
| Forward PE | 128.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,765,794 |
| Open | 33.20 |
| Previous Close | 33.36 |
| Day's Range | 32.50 - 34.76 |
| 52-Week Range | 10.36 - 35.22 |
| Beta | 0.90 |
| Analysts | Strong Buy |
| Price Target | 29.17 (-15.27%) |
| Earnings Date | Aug 15, 2026 |
About Genscript Biotech
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Bio... [Read more]
Analyst Summary
According to 8 analysts, the average rating for 1548 stock is "Strong Buy." The 12-month stock price target is $29.17, which is a decrease of -15.27% from the latest price.
News
Genscript Biotech Earnings Call Transcript: H1 2026
Revenue grew 27.3% year-over-year to $404.2 million, with adjusted net profit up over 200%. AI-driven demand and platform investments are fueling high-margin growth, especially in Life Science and ProBio segments. Guidance for 2026 was raised across all business lines.
Genscript Biotech Earnings release: H1 2026
Genscript Biotech released its H1 2026 earnings on August 16, 2026, summarizing the period's financial results.
Genscript Biotech Slides: H1 2026
Genscript Biotech has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 16, 2026.
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Group Performance Revenue: US$959.5 million, +61.4% year-on-year Gross profit: US$553.2 million, +103.3% year-on-year Adjusted net profit: US$230.3 million, +285.0% year-on-year Business Units' Perfor...
Genscript Biotech Earnings Call Transcript: H2 2025
Revenue grew 61.4% year-over-year to $959.5 million, with adjusted net profit up 285% to $230.3 million. All segments delivered strong growth, driven by innovation, automation, and global expansion. 2026 guidance targets continued double-digit growth and margin improvement.
Genscript Biotech Annual report: H2 2025
Genscript Biotech has published its H2 2025 annual report on March 15, 2026.
Genscript Biotech Earnings release: H2 2025
Genscript Biotech released its H2 2025 earnings on March 15, 2026, summarizing the period's financial results.
Genscript Biotech Slides: H2 2025
Genscript Biotech has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 15, 2026.
Genscript Biotech Slides: FY 2025
Genscript Biotech has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 12, 2025.
Genscript Biotech Earnings Call Transcript: H1 2025
Revenue grew 81.9% year-over-year to $519 million, with all segments expanding and adjusted profit from continuing operations reaching $178 million. ProBio saw a 511% revenue jump, driven by Lenovo payments, while Life Science and Bestzyme posted steady growth. Strong cash reserves and global expansion support continued investment and margin resilience.
Genscript Biotech Quarterly report: H1 2025
Genscript Biotech has published its H1 2025 quarterly earnings report on August 17, 2025.
Genscript Biotech Earnings release: H1 2025
Genscript Biotech released its H1 2025 earnings on August 17, 2025, summarizing the period's financial results.
Genscript Biotech Slides: H1 2025
Genscript Biotech has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 17, 2025.
GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation
Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation PISCATAWAY, N.J. , Aug. 17, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a...
GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader
PISCATAWAY, N.J. , July 31, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that its ESG ra...
GenScript Biotech Corporation Reports FY 2024 Results
Strategic deconsolidation of Legend Biotech unlocked significant value, while core businesses experienced rapid growth. PISCATAWAY, N.J.
Genscript Biotech Earnings Call Transcript: H2 2024
Revenue grew 6.1% to $590M, with strong Life Science and Bestzyme growth offsetting ProBio's decline. A $3.2B one-time gain from Legend Biotech deconsolidation drove net profit, while 2025 guidance targets double-digit growth for all segments and stable margins.
Genscript Biotech Annual report: H2 2024
Genscript Biotech has published its H2 2024 annual report on March 11, 2025.
Genscript Biotech Earnings release: H2 2024
Genscript Biotech released its H2 2024 earnings on March 11, 2025, summarizing the period's financial results.
Genscript Biotech Slides: H2 2024
Genscript Biotech has posted slides in relation to its H2 2024 quarterly earnings report, which was published on March 11, 2025.
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development
LONDON , Nov. 21, 2024 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of its GenScript Biotech G...
GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia
PISCATAWAY, N.J. , Nov. 10, 2024 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript"), a global leader in life sciences services and products, has announced the establishment of new operations ...
Legend Biotech announces cilta-cel approval in China for multiple myeloma
Legend Biotech (LEGN), a subsidiary of GenScript Biotech Corporation (GNNSF), announced they have received approval from the China National Medical Products Administration for its cell therapy product...
Genscript Biotech Earnings Call Transcript: H1 2024
Revenue grew 43.5% year-over-year to $561.4M, led by Legend's 156% growth from Carvykti. Life Science and Bestzyme segments delivered solid results, while ProBio faced headwinds but showed signs of recovery. Guidance remains positive for H2, with capacity expansions underway.
Genscript Biotech Quarterly report: H1 2024
Genscript Biotech has published its H1 2024 quarterly earnings report on August 11, 2024.